In this single-center, single-blind, randomized, placebo-controlled pilot trial. The effect of Racecadotril on the improvement of organ function will be investigated in patients with sepsis. Researchers will screen patients admitted to the Department of Critical Care Medicine at Zhujiang Hospital to identify patients with sepsis based on including and excluding criteria and obtain informed consent and randomize them into groups. On the basis of standardized treatment for sepsis, the Racecadotril group will be given Racecadotril Granules at a dose of 1.5mg/kg reconstituted in 20ml of water for nasal feeding tube, three times daily; the Control group will be given an 20ml of water for nasal feeding tube,three times daily. The changes in SOFA-2 score and other clinically meaningful outcomes in 4 days will be collected. For subjects whose treatment lasts less than 4 days, the changes on the date of ICU discharge will be used.
Investigational drug: Racecadotril Granules Study title: Racecadotril for Organ Injury in Sepsis Patients: A Single-Center, Single-Blind, Randomized, Placebo-Controlled Pilot Trial Principal Investigator: Zhanguo Liu, professor, Department of Critical Care Medicine, Zhujiang Hospital, Southern Medical University Study subjects: Patients diagnosed with sepsis according to the SOFA-2 scoring criteria published by JAMA in 2025 (PMID: 41159833). Study objectives: The objective of the study is to determine whether Racecadotril, compared to placebo, improves organ dysfunction scores (SOFA -2 scores) in septic patients. Study design: A single-center, single-blind, randomized, placebo-controlled pilot trial. Method: On the basis of standardized treatment for sepsis, the Racecadotril group will be given Racecadotril Granules at a dose of 1.5mg/kg reconstituted in 20ml of water for nasal feeding tube, three times daily; the Control group will be given an equal volume of water for nasal feeding tube,three times daily, intervention for 4 days or until ICU discharge(whatever come first). Course: 4 days Sample size: 44 The number of study center: 1 Study center: 1\. Department of Critical Care Medicine of Zhujiang Hospital,Southern Medical University,Guangzhou, China Primary endpoint: 96-hour Sequential Organ Failure Assessment-2 (SOFA-2) score Secondary endpoints: 1. The blood routine examination: White blood cell count, neutrophil count, neutrophil ratio, lymphocyte count, lymphocyte ratio, platelet count at 96 h after first treatment administration. 2. The state of liver function: the serum level of transaminase (AST and ATL) and total bilirubin at 96 h after first treatment administration. 3. The state of kidney function: the serum level of Creatinine (Cr)#blood urea nitrogen (BUN)# and daily urine output at 96 h after first treatment administration. 4. The state of circulation system: Blood pressure, the duration and dosage of vasopressor drugs, and the serum level of lactate at 96 h after first treatment administration. 5. The state of lung function: oxygenation index(PaO2/FiO2), partial pressure of oxygen, partial pressure of carbon dioxide at 96 h after first treatment administration. 6. The state of inflammatory response: the serum level of interleukin-6(L-6) and C-reactive protein (CRP) at 96 h after first treatment administration. 7. The state of infection: the serum level of procalcitonin (PCT) at 96 h after first treatment administration. 8. The organ function support status: mechanical ventilation, RT treatment status, ECMO support status at 96 h after first treatment administration. 9. The critical score: APAPCHE II score at 96 h after first treatment administration. Safety endpoints: 1. Safety evaluation indicators: Possible adverse reactions of Racecadotril may include (drowsiness, rash, constipation, nausea, abdominal pain), survival status on the 28th day. 2. Feasibility evaluation indicators: Record the specific number of days and times that patients used Racecadotril; ICU hospitalization days. For subjects whose treatment lasts less than 4 days, the changes on the date of ICU discharge will be used.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Enrollment
44
On the basis of standardized treatment for sepsis, the Racecadotril group will be given Racecadotril Granules at a dose of 1.5mg/kg reconstituted in 20ml of water for nasal feeding tube, three times daily for 4 consecutive days
On the basis of standardized treatment for sepsis, 20ml of water for nasal feeding tube, three times daily for 4 consecutive days
Department of Critical Care Medicine of Zhujiang Hospital,Southern Medical University
Guanzhou, Guangdong, China
96-hour Sequential Organ Failure Assessment-2 (SOFA-2) score
The SOFA-2 score is the Sequential Organ Failure Score-2, which is used to assess a patient's prognosis by determining the degree of impairment of major organ function. The score is divided into 6 sections: respiratory, coagulation, hepatic, cardiovascular, central nervous system, and renal, and ranges from 0 to 4, resulting in a total score ranging from a minimum of 0 to a maximum of 24 points, with higher SOFA-2 scores associated with a higher incidence of poor prognosis.
Time frame: Day0,Day1,Day2,Day3,Day4
blood routine examination(1) - white blood cell count
white blood cell count
Time frame: Day0,Day1,Day2,Day3,Day4
blood routine examination(2) - neutrophil count
neutrophil count
Time frame: Day0,Day1,Day2,Day3,Day4
blood routine examination(3) - neutral cytoplasmic ratio
neutral cytoplasmic ratio
Time frame: Day0,Day1,Day2,Day3,Day4
blood routine examination(4) - lymphocyte count
lymphocyte count
Time frame: Day0,Day1,Day2,Day3,Day4
blood routine examination(5) - lymphocyte ratio
lymphocyte ratio
Time frame: Day0,Day1,Day2,Day3,Day4
blood routine examination(6) - platelet count
platelet count
Time frame: Day0,Day1,Day2,Day3,Day4
liver function(1) - ALT
the serum level of Alanine transaminase(ALT)
Time frame: Day0,Day1,Day2,Day3,Day4
liver function(2) - AST
the serum level of Aspartate transaminase (AST)
Time frame: Day0,Day1,Day2,Day3,Day4
liver function(3) - TBil
the serum level of total bilirubin(TBil)
Time frame: Day0,Day1,Day2,Day3,Day4
kidney function(1) - Cr
serum level of Creatinine (Cr)
Time frame: Day0,Day1,Day2,Day3,Day4
kidney function(2) - BUN
serum level of blood urea nitrogen(BUN)
Time frame: Day0,Day1,Day2,Day3,Day4
kidney function(3) - daily urine output
daily urine output in milliliters from 0:00 - 24:00
Time frame: Day0,Day1,Day2,Day3,Day4
circular evaluation index(1) - BP
blood pressure
Time frame: Day0,Day1,Day2,Day3,Day4
circular evaluation index(2) - the duration and dosage of vasoactive drugs
the duration and dosage of vasoactive drugs. The duration from the vasoactive drugs administration to the successful cessation in hours( The successful cessation is defined as the attainment of a clinician-prescribed mean arterial pressure target for more than 24-hours without the use of vasoactive drugs. This outcome measure is intended only for patients receiving vasoactive drugs)
Time frame: Day0,Day1,Day2,Day3,Day4
circular evaluation index(3) - Lac
the serum level of lactic acid
Time frame: Day1,Day2,Day3,Day4
lung function(1) - PaO2/FiO2
oxygenation index(PaO2/FiO2),the patients treated with extracorporeal membrane oxygenation will not collect this indicator
Time frame: Day0,Day1,Day2,Day3,Day4
lung function(2) - PaO2
oxygen partial pressure(PaO2)
Time frame: Day0,Day1,Day2,Day3,Day4
lung function(3) - PaCO2
partial pressure of carbon dioxide(PaCO2)
Time frame: Day0,Day1,Day2,Day3,Day4
inflammatory response(1) - CRP
the serum level of C-reactive protein(CRP)
Time frame: Day0,Day1,Day2,Day3,Day4
inflammatory response(2) - IL-6
the serum level of interleukin-6(IL-6)
Time frame: Day0,Day1,Day2,Day3,Day4
Indicators of infection
the serum level of procalcitonin(PCT)
Time frame: Day0,Day1,Day2,Day3,Day4
organ function support status(1) - the duration of use of MV
the duration of use of mechanical ventilation (MV).The duration from the MV administration to the successful cessation in hours( The successful cessation is defined as the termination of MV for more than 48-hours. This outcome measure is intended only for patients receiving MV)
Time frame: Day0,Day1,Day2,Day3,Day4
organ function support status(2) - The duration of CRRT
The duration of CRRT.The duration of CRRT therapy in hours
Time frame: Day0,Day1,Day2,Day3,Day4
organ function support status(3) - The duration of ECMO
The duration of ECMO.The duration of ECMO therapy in hours
Time frame: Day0,Day1,Day2,Day3,Day4
The critical score - APAPCHE II score
APAPCHE II score (Acute Physiology and Chronic Health Evaluation II) has a scoring range of 0 to 71 points. A higher score indicates a worse outcome, signifying a more critical patient condition and a correspondingly increased risk of mortality. It is a commonly used tool in Intensive Care Units (ICUs) for assessing the severity of a patient's illness and predicting prognosis.
Time frame: Day0,Day1,Day2,Day3,Day4
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.